Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00187525
NCT00187525CompletedPhase 4

A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

University of California, San Francisco0 sitesStarted: May 2004Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Neary et al. Criteria for Frontotemporal Lobar Degeneration
  • •Age 40 -80
  • •CDR < 3 or MMSE > 15
  • •English Speaking
  • •Study Partner

Exclusion Criteria

  • •Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Completed
Phase 1
A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State MemantineHealthy Volunteer
NCT01196065Hoffmann-La Roche16
Recruiting
Not Applicable
An open-label trial of memantine for the treatment of posttraumatic stress disorderposttraumatic stress disorder
JPRN-jRCTs031180200Kim Yoshiharu20
Completed
Not Applicable
An open-label trial of memantine for the treatment of posttraumatic stress disorder
JPRN-UMIN000022467ational Institute of Mental Health, National Center of Neurology and Psychiatry20
Completed
Phase 4
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOSADHD
NCT00586573Massachusetts General Hospital34
Completed
Phase 2
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With AutismAutism
NCT00872898Forest Laboratories124